SVB Leerink started coverage on shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) in a report released on Monday, Marketbeat.com reports. The firm issued an outperform rating and a $15.00 target price on the biotechnology company’s stock. SVB Leerink also issued estimates for Alpine Immune Sciences’ Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.58) EPS, FY2023 earnings at ($1.31) EPS, FY2024 earnings at ($2.49) EPS, FY2025 earnings at ($2.99) EPS and FY2026 earnings at ($3.11) EPS.
Several other research analysts have also recently issued reports on ALPN. Oppenheimer decreased their price objective on shares of Alpine Immune Sciences from $17.00 to $14.00 and set an outperform rating for the company in a report on Monday, October 24th. Wedbush increased their target price on shares of Alpine Immune Sciences to $25.00 in a research report on Thursday, September 15th. Finally, HC Wainwright cut their target price on shares of Alpine Immune Sciences from $21.00 to $8.00 in a research report on Monday, October 24th.
Alpine Immune Sciences Trading Down 3.7 %
NASDAQ ALPN opened at $6.27 on Monday. The company has a 50-day moving average price of $6.52 and a two-hundred day moving average price of $7.80. The stock has a market cap of $190.61 million, a price-to-earnings ratio of -3.50 and a beta of 1.39. Alpine Immune Sciences has a 52 week low of $4.82 and a 52 week high of $14.40.
Institutional Inflows and Outflows
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.